

Poster (Stand 10/2023)

- P 011** Galun D, Tröger W, Reif M, Schumann A, Stancović N, Milićević M: Mistletoe extract therapy versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized clinical phase III trial on overall survival. *Annals of Oncology*, Vol. 23, suppl. 9, 2012, 9:712P
Entspricht
A 029
- P 010** Zajicek J, Reif M, Schnelle M on behalf of the MUSEC study investigators: Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis – results of the MUSEC study. Poster ECTRIMS, 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis, September 9-12, 2009, Düsseldorf, Germany
Entspricht
A 025
- P 009** Büssing A, Bückner U, Enser-Weis U, Schnelle M, Schumann A, Schietzel M, Hatzmann W, Hackmann J: Randomisierte Phase-II-Studie zur Modulation einer chemotherapiebedingten Immunsuppression durch Mistelextrakt-Infusionen. Poster zur Studie 23-01, Wissenschaftstage 2007 an der Uni Witten/ Herdecke, 01.-02. Juni 2007
- P 008** Kröz M, Reif M, Debus M, Girke M, Humbroich K, Von Laue H.B, Brauer D: Validation of a New Scale on Internal Coherence (ICS) with Mistletoe-Sensitive Questions for Cancer Patients. 4th Mistletoe Symposium, 15. Oktober 2007, *Phytomedicine* 14 (2): S53
- P 007** Kröz M, Feder G, Brauer D, Von Laue H.B, Reif M, Girke M, Riess O.H, Zerm F, Schad F: Reliability, Validity and Mistletoe Sensitivity of the German Version of the Cancer Fatigue Scale (CFS-D). 4th Mistletoe Symposium, 15. Oktober 2007, *Phytomedicine* 14 (2): S33
- P 006** Holdcroft A; Maze M; Tebbs S; Doré C: An Escalating Dose Study of cannador for postoperativce pain: Dose related effects. Studie 21-05(CANPOP), IACM 2nd Conference on Cannabinoids in Medicine, Köln 12.-13. September 2003
- P 005** Ernst G; Denke C; Reif M; Schnelle M; Hagmeister H: Standardized Cannabis Extract in the treatment of postzosteric neuralgia- a randomized, double-blind, placebo-controlled cross-over study. World congress on Pain, Sydney 21.-26. August 2005
Entspricht
A 017
- P 004** Kröz M; Reif M; Zerm M; von Laue B; Brauer D; Heckmann C; Debus M; Bartsch C: Results of a discrimination analysis between patients with breast- and colon carcinoma. 27. Deutscher Krebskongress, Berlin 22.-26. März 2006
- P 003** Kröz M; Schneider A; Brauer D; Zerm R; Reif M; Kirchhoff M; von Laue HB; Girke, M: Reliabilität und Validität der deutschen Version der Cancer Fatigue Scale (CFS-D). 110. Jahrestagung der DGIM (Deutsche Gesellschaft für Innere Medizin), Wiesbaden, 17.-21.April 2004

P 002 Kröz M, Zerm R, Laue HB von, Brauer D, Reif M, Heckmann C, Girke M:
Entspricht Regulationsverlust internistischer Patienten gemessen mit einem neuen
A 012 Fragebogen zur endogenen Regulation. 109. Jahrestagung der DGIM
(Deutsche Gesellschaft für Innere Medizin), Wiesbaden, 26.-30. April 2003

P 001 Strasser F, Schnelle M, Kuechler T, Reif M, Cerny T: How to study patients
Entspricht with cancer anorexia/cachexia syndrome (CCS): "work in progress report"
A 009 from a placebo-controlled phase III trial with emphasis on the difficulties to
define an adequate patient population and on the development of outcome
measurement instruments. 1. Kongress des Research Network der European
Association for Palliative Care, Berlin 7.-9. Dezember 2000